Patents by Inventor Elvire Gouze

Elvire Gouze has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
    Patent number: 11814654
    Abstract: The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a prolonged activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: November 14, 2023
    Assignees: Institut National de la Sante et de la Recherche Medicale, Université Paul Sabatier Toulouse III
    Inventor: Elvire Gouze
  • Soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
    Patent number: 11702642
    Abstract: The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: July 18, 2023
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paul Sabatier Toulouse III
    Inventor: Elvire Gouze
  • Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
    Patent number: 11697678
    Abstract: The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth regardation disorders, such as achondroplasia.
    Type: Grant
    Filed: April 20, 2021
    Date of Patent: July 11, 2023
    Assignees: Pfizer Inc., INSERM (Institut National de la Santé et de la Recherche Médicale), Université Côte d'Azur
    Inventors: Elvire Gouze, Stéphanie Garcia
  • HYBRID PROMOTERS AND THEIR USES IN THERAPY, NOTABLY FOR TREATING TYPE II COLLAGENOPATHIES
    Publication number: 20220290131
    Abstract: The present invention relates to hybrid promoters with a specific design, comprising fragments of the hCOL2A1 promoter and fragments of the hEF1? promoter, which may be of interest in therapy, particularly in gene therapy. Notably, they may be introduced into a vector for expressing a nucleic acid sequence of interest. They may be particularly useful for treating skeletal dysplasia, such as type II collagenopathies; or articular diseases.
    Type: Application
    Filed: December 18, 2019
    Publication date: September 15, 2022
    Inventor: Elvire GOUZE
  • SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (SFGFR3) POLYPEPTIDES AND USES THEREOF
    Publication number: 20210309718
    Abstract: The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth regardation disorders, such as achondroplasia.
    Type: Application
    Filed: April 20, 2021
    Publication date: October 7, 2021
    Applicants: Pfizer Inc., INSERM (Institut National de la Santé et de la Recherche Médicale), Université Côte d'Azur
    Inventors: Elvire Gouze, Stéphanie Garcia
  • Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
    Patent number: 11021528
    Abstract: The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth retardation disorders, such as achondroplasia.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: June 1, 2021
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale, Pfizer Inc., Université Côte d'Azur
    Inventors: Elvire Gouze, Stéphanie Garcia
  • SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGR3) POLYPEPTIDE FOR USE IN THE PREVENTION OR TREATMENT OF SKELETAL GROWTH RETARDATION DISORDERS
    Publication number: 20210032607
    Abstract: The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FG-FR3), in particular by expression of a constitutively activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia.
    Type: Application
    Filed: March 13, 2020
    Publication date: February 4, 2021
    Applicants: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paul Sabatier Toulouse III
    Inventor: Elvire Gouze
  • SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGR3) POLYPEPTIDE FOR USE IN THE PREVENTION OR TREATMENT OF SKELETAL GROWTH RETARDATION DISORDERS
    Publication number: 20210032608
    Abstract: The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FG-FR3), in particular by expression of a prolonged activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia.
    Type: Application
    Filed: June 19, 2020
    Publication date: February 4, 2021
    Applicants: Institut National de la Sante et de la Recherche Medicale, Université Paul Sabatier Toulouse III
    Inventor: Elvire Gouze
  • SOLUBLE FGFR3 DECOYS FOR TREATING SKELETAL GROWTH DISORDERS
    Publication number: 20210009657
    Abstract: The invention features soluble FGF decoy polypeptides and fusion polypeptides comprising an FGF decoy polypeptide linked to a heterologous polypeptide, such as an aggrecan binding protein. Both soluble FGF decoy polypeptides and fusion polypeptides can be used to prevent or treat skeletal disorders, such as achondroplasia.
    Type: Application
    Filed: February 20, 2020
    Publication date: January 14, 2021
    Applicants: Pfizer Inc., INSERM (Institut National de la Sante et de la Recherche Medicale), Université Côte d'Azur
    Inventors: Elvire Gouze, Stéphanie Garcia
  • TREATMENT OF ABNORMAL VISCERAL FAT DEPOSITION USING SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (SFGFR3) POLYPEPTIDES
    Publication number: 20200297799
    Abstract: The invention features methods of using SFGFR3 polypeptides to treat abnormal visceral fat deposition and the conditions associated with abnormal visceral fat deposition.
    Type: Application
    Filed: September 20, 2018
    Publication date: September 24, 2020
    Applicants: Pfizer Inc., Université Côte d'Azur, INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National de la Recherche Scientifique
    Inventors: Elvire Gouze, Stéphanie Garcia
  • Soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
    Patent number: 10724014
    Abstract: The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FG-FR3), in particular by expression of a prolonged activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia.
    Type: Grant
    Filed: January 16, 2014
    Date of Patent: July 28, 2020
    Assignees: Institut National de la Sante et de la Recherche Medicale, Université Paul Sabatier Toulouse III
    Inventor: Elvire Gouze
  • SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGR3) POLYPEPTIDE FOR USE IN THE PREVENTION OR TREATMENT OF SKELETAL GROWTH RETARDATION DISORDERS
    Publication number: 20200199545
    Abstract: The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FG-FR3), in particular by expression of a constitutively activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia.
    Type: Application
    Filed: August 5, 2019
    Publication date: June 25, 2020
    Inventor: Elvire Gouze
  • SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (SFGFR3) POLYPEPTIDES AND USES THEREOF
    Publication number: 20200190162
    Abstract: The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth retardation disorders, such as achondroplasia.
    Type: Application
    Filed: May 20, 2019
    Publication date: June 18, 2020
    Inventors: Elvire GOUZE, Stéphanie GARCIA
  • Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
    Patent number: 10294289
    Abstract: The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth retardation disorders, such as achondroplasia.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: May 21, 2019
    Assignees: Therachon SAS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE NICE SOPHIA ANTIPOLIS
    Inventors: Elvire Gouze, Stéphanie Garcia
  • SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (SFGFR3) POLYPEPTIDES AND USES THEREOF
    Publication number: 20180230197
    Abstract: The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth retardation disorders, such as achondroplasia.
    Type: Application
    Filed: April 2, 2018
    Publication date: August 16, 2018
    Inventors: Elvire GOUZE, Stéphanie GARCIA
  • SOLUBLE FGFR3 DECOYS FOR TREATING SKELETAL GROWTH DISORDERS
    Publication number: 20180148494
    Abstract: The invention features soluble FGF decoy polypeptides and fusion polypeptides comprising an FGF decoy polypeptide linked to a heterologous polypeptide, such as an aggrecan binding protein. Both soluble FGF decoy polypeptides and fusion polypeptides can be used to prevent or treat skeletal disorders, such as achondroplasia.
    Type: Application
    Filed: January 7, 2016
    Publication date: May 31, 2018
    Applicants: TheAchon, Inserm (Institut National de la Sante et de la Recherche Medicale), Universite Nice Sophia Antipolis
    Inventors: Elvire GOUZE, Stéphanie GARCIA
  • A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders
    Publication number: 20150353624
    Abstract: The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FG-FR3), in particular by expression of a prolonged activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia.
    Type: Application
    Filed: January 16, 2014
    Publication date: December 10, 2015
    Inventor: Elvire GOUZE
  • A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders
    Publication number: 20150344855
    Abstract: The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia.
    Type: Application
    Filed: January 16, 2013
    Publication date: December 3, 2015
    Inventor: Elvire GOUZE
  • METHODS FOR TREATING ARTICULAR DISEASE OR DYSFUNCTION USING SELF-COMPLIMENTARY ADENO-ASSOCIATED VIRAL VECTORS
    Publication number: 20080187576
    Abstract: Disclosed are methods and compositions for treating articular diseases such as osteoarthritis and rheumatoid arthritis, or articular dysfunction in mammals. Also disclosed are self-complimentary AAV vectors useful in gene therapy and delivery of therapeutic constructs to mammalian cells, and in particular, articular joints, cartilage, ligaments, tendons, and surrounding tissues.
    Type: Application
    Filed: June 18, 2007
    Publication date: August 7, 2008
    Applicants: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Steven Craig Ghivizzani, Christopher Howard Evans, Elvire Gouze, Jean-Noel Gouze